Arrowstreet Capital Limited Partnership Sells 99,210 Shares of Charles River Laboratories International, Inc. $CRL

Arrowstreet Capital Limited Partnership decreased its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 11.9% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 737,030 shares of the medical research company’s stock after selling 99,210 shares during the quarter. Arrowstreet Capital Limited Partnership’s holdings in Charles River Laboratories International were worth $127,138,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Tema Etfs LLC bought a new stake in Charles River Laboratories International during the 4th quarter valued at approximately $26,000. Los Angeles Capital Management LLC purchased a new stake in shares of Charles River Laboratories International in the fourth quarter valued at $42,000. Sfam LLC purchased a new stake in shares of Charles River Laboratories International in the fourth quarter worth approximately $43,000. Activest Wealth Management lifted its position in shares of Charles River Laboratories International by 10,900.0% during the fourth quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock worth $44,000 after purchasing an additional 218 shares during the last quarter. Finally, Geneos Wealth Management Inc. boosted its stake in shares of Charles River Laboratories International by 98.0% during the second quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 145 shares during the period. Institutional investors own 98.91% of the company’s stock.

Wall Street Analysts Forecast Growth

CRL has been the topic of several recent analyst reports. CLSA downgraded shares of Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price target on the stock. in a research note on Monday, July 20th. JPMorgan Chase & Co. dropped their target price on shares of Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating on the stock in a research note on Monday, April 13th. Barclays raised their price objective on Charles River Laboratories International from $210.00 to $220.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Royal Bank Of Canada began coverage on Charles River Laboratories International in a research report on Tuesday, April 14th. They set an “outperform” rating and a $215.00 target price for the company. Finally, Sanford C. Bernstein set a $250.00 price objective on shares of Charles River Laboratories International in a report on Wednesday, July 1st. Eleven equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $220.75.

Insider Buying and Selling

In other news, Director James C. Foster sold 75,000 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $225.00, for a total transaction of $16,875,000.00. Following the completion of the sale, the director owned 31,596 shares in the company, valued at approximately $7,109,100. The trade was a 70.36% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.30% of the stock is owned by corporate insiders.

Charles River Laboratories International Trading Down 1.3%

CRL stock opened at $226.38 on Friday. The stock has a market cap of $10.90 billion, a price-to-earnings ratio of -60.21, a PEG ratio of 2.52 and a beta of 1.40. Charles River Laboratories International, Inc. has a 12-month low of $144.26 and a 12-month high of $238.85. The business’s 50-day moving average is $198.80 and its 200 day moving average is $187.51. The company has a current ratio of 1.36, a quick ratio of 1.03 and a debt-to-equity ratio of 0.90.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Thursday, May 7th. The medical research company reported $2.06 EPS for the quarter, beating analysts’ consensus estimates of $1.96 by $0.10. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The company had revenue of $995.83 million for the quarter, compared to analysts’ expectations of $977.46 million. During the same quarter in the prior year, the company posted $2.34 earnings per share. Charles River Laboratories International’s revenue for the quarter was up 1.2% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. On average, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 11.05 EPS for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.